The single pill would target all three major bloodstream lipids – – LDL-C ‘bad’ cholesterol, HDL-C ‘great’ cholesterol, and triglycerides. ABT-335 is usually Abbott’s next-generation fenofibrate presently in late-stage medical trials. Based on the significant progress manufactured in the ABT-335 and CRESTOR fixed-dose mixture development program, the companies are determined to move forward with this fixed-dosage combination therapy jointly. The studies are proceeding on schedule. Related StoriesBlocking calcium-signaling pathway could inhibit Ebola virus and other sources of deadly infectionsFour microRNAs appear to play critical functions in controlling cholesterol, triglyceride metabolismNew vaccine appears to be more effective in reducing 'awful' LDL cholesterol’This decision highlights the opportunity for broader treatment in lots of higher at-risk populations,’ said Eugene Sunlight, M.D., vice president, Global Pharmaceutical Clinical Advancement, Abbott.Over twelve months, the resveratrol group showed a stabilization in the amount of a proteins – – called amyloid-beta 40 – – within their spinal fluid. In contrast, those known levels declined in the placebo group. That’s essential, Hendrix explained, because levels of amyloid-beta 40 in the spinal fluid normally lower as Alzheimer’s worsens. The theory is that even more of the protein is being deposited in the brain, where it contributes to the irregular plaques that mark Alzheimer’s.